{"product_id":"ovarian-cancer-market-global-industry-trends-share-size-growth-opportunity-and-forecast-2023-2028","title":"Ovarian Cancer Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028","description":"\u003cp\u003eOvarian Cancer Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028\u003cbr\u003e\nMarket Overview:\u003c\/p\u003e\n\n\u003cp\u003eThe global ovarian cancer market size reached US$ 1.9 Billion in 2022. Looking forward, IMARC Group expects the market to reach US$ 3.7 Billion by 2028, exhibiting a growth rate (CAGR) of 11.56% during 2023-2028.\u003c\/p\u003e\n\n\u003cp\u003eOvarian cancer refers to a malignant tumor wherein abnormal cells in the ovary begin to multiply and grow uncontrollably from the outer tissue lining or fallopian tubes due to mutagenic changes in the deoxyribonucleic acid (DNA). At present, it can be treated with the support of various diagnoses and drugs, including antirheumatics, antineoplastics, and PARP, mitotic, and VEGF\/VEGFR inhibitors. Apart from this, ovarian cancer treatment involves surgery, chemotherapy, hormone, radiation, and targeted therapies that help kill cancer cells to provide relief from signs and systems. These therapeutics are executed by medical practitioners after determining multiple factors, such as the spread of the tumor, individuals’ general health, and the size and type of ovarian cancer.\u003c\/p\u003e\n\n\u003cp\u003eOvarian Cancer Market Trends:\u003cbr\u003e\nThe increasing prevalence of epithelial, stromal, and germ cell ovarian cancer, especially amongst the female geriatric population, due to the genetic mutation of breast cancer gene 1 (BRCA1) or BRCA2, is primarily driving the market growth. In line with this, the rising need for effective therapeutic drugs, such as bevacizumab (Avastin) and pazopanib (Votrient), is acting as another growth-inducing factor. Additionally, the widespread adoption of combination therapies in the healthcare sector to prevent drug resistance and increase treatment efficacy is supporting the market growth. Moreover, the ongoing patent expiration of branded medications has prompted governments and pharmaceutical companies to launch novel recombinant drugs, which, in turn, is propelling market growth. Furthermore, extensive initiatives undertaken by non-governmental organizations (NGOs) to sensitize consumers regarding the symptoms, treatments, and benefits of early ovarian cancer diagnosis are impelling the market growth. Apart from this, strategic collaborations amongst key players and continuous research and development (R\u0026amp;D) activities to produce efficient therapeutic interventions are creating a positive outlook for the market.\u003c\/p\u003e\n\n\u003cp\u003eKey Market Segmentation:\u003cbr\u003e\nIMARC Group provides an analysis of the key trends in each sub-segment of the global ovarian cancer market report, along with forecasts at the global, regional and country level from 2023-2028. Our report has categorized the market based on type, treatment type and end user.\u003c\/p\u003e\n\n\u003cp\u003eBreakup by Type:\u003c\/p\u003e\n\n\u003cp\u003eEpithelial Ovarian Cancer\u003cbr\u003e\nGerm Cell Ovarian Cancer\u003cbr\u003e\nStromal Cell Ovarian Cancer\u003cbr\u003e\n \u003cbr\u003e\nBreakup by Treatment Type:\u003c\/p\u003e\n\n\u003cp\u003eImmunotherapy\u003cbr\u003e\nChemotherapy\u003cbr\u003e\nTargeted Therapy\u003cbr\u003e\nSurgery\u003cbr\u003e\nOthers\u003cbr\u003e\n \u003cbr\u003e\nBreakup by End User:\u003c\/p\u003e\n\n\u003cp\u003eHospitals\u003cbr\u003e\nHomecare\u003cbr\u003e\nSpeciality Centre\u003cbr\u003e\nOthers\u003cbr\u003e\n \u003cbr\u003e\nBreakup by Region:\u003c\/p\u003e\n\n\u003cp\u003eNorth America\u003cbr\u003e\nUnited States\u003cbr\u003e\nCanada\u003cbr\u003e\nAsia-Pacific\u003cbr\u003e\nChina\u003cbr\u003e\nJapan\u003cbr\u003e\nIndia\u003cbr\u003e\nSouth Korea\u003cbr\u003e\nAustralia\u003cbr\u003e\nIndonesia\u003cbr\u003e\nOthers\u003cbr\u003e\nEurope\u003cbr\u003e\nGermany\u003cbr\u003e\nFrance\u003cbr\u003e\nUnited Kingdom\u003cbr\u003e\nItaly\u003cbr\u003e\nSpain\u003cbr\u003e\nRussia\u003cbr\u003e\nOthers\u003cbr\u003e\nLatin America\u003cbr\u003e\nBrazil\u003cbr\u003e\nMexico\u003cbr\u003e\nOthers\u003cbr\u003e\nMiddle East and Africa\u003cbr\u003e\n \u003cbr\u003e\nCompetitive Landscape:\u003cbr\u003e\nThe competitive landscape of the industry has also been examined along with the profiles of the key players being AbbVie Inc., Amneal Pharmaceuticals Inc., AstraZeneca plc, Eli Lilly and Company, F. Hoffmann-La Roche AG, GSK plc, Hikma Pharmaceuticals PLC, Lupin Limited, Pfizer Inc. and Teva Pharmaceutical Industries Ltd.\u003c\/p\u003e\n\n\u003cp\u003eKey Questions Answered in This Report:\u003cbr\u003e\nHow has the global ovarian cancer market performed so far and how will it perform in the coming years?\u003cbr\u003e\nWhat has been the impact of COVID-19 on the global ovarian cancer market?\u003cbr\u003e\nWhat are the key regional markets?\u003cbr\u003e\nWhat is the breakup of the market based on the type?\u003cbr\u003e\nWhat is the breakup of the market based on the treatment type?\u003cbr\u003e\nWhat is the breakup of the market based on the end user?\u003cbr\u003e\nWhat are the various stages in the value chain of the industry?\u003cbr\u003e\nWhat are the key driving factors and challenges in the industry?\u003cbr\u003e\nWhat is the structure of the global ovarian cancer market and who are the key players?\u003cbr\u003e\nWhat is the degree of competition in the industry?\u003c\/p\u003e","brand":"Life Science","offers":[{"title":"October, 2023 \/ 142 Pages \/ MCW16255774","offer_id":47650499658034,"sku":null,"price":2999.0,"currency_code":"USD","in_stock":true}],"url":"https:\/\/www.hardmanwell.com\/products\/ovarian-cancer-market-global-industry-trends-share-size-growth-opportunity-and-forecast-2023-2028","provider":"HARDMAN AND WELL MANAGEMENT CONSULTANCIES L.L.C","version":"1.0","type":"link"}